Skip to main content

Diabetes

  • New research examines cost-effectiveness of lowering HbA1C cutoff

    NEW YORK — Reducing the cutoff of hemoglobin A1C to determine if a patient has prediabetes could be cost effective, according to a new study.

  • Staying seated could up diabetes risk for women, study finds

    NEW YORK — Women that are seated for longer periods of time are more likely to develop diabetes when compared with men, according to a new study.

  • Study: H. pylori may be linked to diabetes risk

    NEW YORK — A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

  • Pfizer, Biocon end biosimilar insulin deal

    NEW YORK — Pfizer and Indian drug maker Biocon have ended a partnership that the companies started in 2010 to develop biosimilar treatments for diabetes, the companies said.

  • CHPA: Economy, social media changing how America shops 'health'

    BONITA SPRINGS, Fla. — In excess of $102 billion. That's the value over-the-counter medicine delivers to the U.S. healthcare system, Consumer Healthcare Products Association leaders shared with attendees of the CHPA Annual Executive Conference held here Friday morning.

  • APhA, ADA announce new collaboration

    WASHINGTON — A new partnership aims to educate pharmacists, other healthcare professionals, caregivers and patients about diabetes and about how pharmacists can work with physicians to help patients manage the condition.

    The American Pharmacists Association, the APhA Foundation and the American Diabetes Association announced the collaboration Friday, saying it would develop new resources and also promote existing programs, such as the ADA's Stop Diabetes Movement and the APhA's Pharmaceutical Care for Patients with Diabetes certification program.

  • FDA committee to discuss anti-NGF drug class at meeting

    WASHINGTON — A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

  • MTM fights diabetes on the front lines

    The number of patients with diabetes is not decreasing any time soon, and one of the most important fronts in the battle lies at the pharmacy counter.


X
This ad will auto-close in 10 seconds